Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 1Z9
- Forest Investigative Site #050
-
Vancouver, British Columbia, Canada, V6Z 2L4
- Forest Investigative Site #051
-
-
Nova Scotia
-
Sydney, Nova Scotia, Canada, B1S 2E8
- Forest Investigative Site #052
-
-
Ontario
-
Chatham, Ontario, Canada, N7M 1B7
- Forest Investigative Site #055
-
Ottawa, Ontario, Canada, K1G 4G3
- Forest Investigative Site #053
-
-
-
-
California
-
Beverly Hills, California, Forenede Stater, 90210
- Forest Investigative Site #023
-
Encino, California, Forenede Stater, 31316
- Forest Investigative Site #017
-
Garden Grove, California, Forenede Stater, 92845
- Forest Investigative Site #021
-
Newport Beach, California, Forenede Stater, 92660
- Forest Investigative Site #025
-
Orange, California, Forenede Stater, 92868
- Forest Investigative Site #030
-
San Diego, California, Forenede Stater, 92108
- Forest Investigative Site #002
-
Sherman Oaks, California, Forenede Stater, 91403
- Forest Investigative Site #003
-
-
Florida
-
Bonita Springs, Florida, Forenede Stater, 34134
- Forest Research Institute #001
-
Fort Myers, Florida, Forenede Stater, 33912
- Forest Investigative Site #015
-
Maitland, Florida, Forenede Stater, 32751
- Forest Investigative Site #029
-
North Miami, Florida, Forenede Stater, 33161
- Forest Investigative Site #005
-
Orlando, Florida, Forenede Stater, 32806
- Forest Investigative Site #016
-
South Miami, Florida, Forenede Stater, 33143
- Forest Investigative Site #004
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30328
- Forest Investigative Site #014
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60634
- Forest Investigative Site #022
-
Chicago, Illinois, Forenede Stater, 60640
- Forest Investigative Site #006
-
-
Kansas
-
Prairie Village, Kansas, Forenede Stater, 66206
- Forest Investigative Site #009
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21208
- Forest Investigative Site #013
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02135
- Forest Investigative Site #010
-
-
Missouri
-
Saint Louis, Missouri, Forenede Stater, 63139
- Forest Investigative Site #012
-
-
New York
-
Staten Island, New York, Forenede Stater, 10312
- Forest Investigative Site #011
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97210
- Forest Investigative Site #026
-
-
Pennsylvania
-
Bridgeville, Pennsylvania, Forenede Stater, 15017
- Forest Investigative Site #008
-
Norristown, Pennsylvania, Forenede Stater, 19401
- Forest Investigative Site #028
-
Philadelphia, Pennsylvania, Forenede Stater, 19139
- Forest Investigative Site #020
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38119
- Forest Investigative Site #024
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75231
- Forest Investigative Site #007
-
San Antonio, Texas, Forenede Stater, 78229
- Forest Investigative Site #019
-
-
Washington
-
Bellevue, Washington, Forenede Stater, 98007
- Forest Investigative Site #018
-
Seattle, Washington, Forenede Stater, 98104
- Forest Investigative Site #027
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Men and women, 18-65 years old
- Currently meet the DSM-IV-TR criteria for Major Depressive Disorder
- The patient's current depressive episode must be at least 4 weeks in duration
Exclusion Criteria:
- Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control
Patients with a history of meeting DSM-IV-TR criteria for:
- any manic or hypomanic episode
- schizophrenia or any other psychotic disorder
- obsessive-compulsive disorder
- Patients who are considered a suicide risk
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: 2
40, 80 or 120 mg/day Levomilnacipran ER capsules, oral administration, once daily dosing.
|
Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
|
|
Placebo komparator: 1
Matching placebo capsules, oral administration, once daily dosing.
|
Matching placebo to be given orally, in capsule form, once daily.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to Relapse (Days)
Tidsramme: 24 Weeks
|
Number of days until patients meet relapse criteria.
Relapse was defined as 1 or more of the following: 1. MADRS total score of at least 22 at 2 consecutive visits 2. Increase of 2 or more points in CGI-I score compared with the CGI-I score at Visit 9 at 2 consecutive visits 3. Premature discontinuation due to insufficient therapeutic response 4. MADRS item 10 score of at least 4
|
24 Weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Adfærdsmæssige symptomer
- Psykiske lidelser
- Stemningsforstyrrelser
- Depression
- Depressiv lidelse
- Depressiv lidelse, major
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Agenter fra det perifere nervesystem
- Analgetika
- Sensoriske systemagenter
- Analgetika, ikke-narkotisk
- Psykotropiske stoffer
- Neurotransmitter optagelseshæmmere
- Membrantransportmodulatorer
- Antidepressive midler
- Serotonin- og Noradrenalin-genoptagelseshæmmere
- Milnacipran
- Levomilnacipran
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- LVM-MD-05
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .